These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 26961375

  • 1. Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
    Olivier CB, Weik P, Meyer M, Weber S, Diehl P, Bode C, Moser M, Zhou Q.
    J Thromb Thrombolysis; 2016 Aug; 42(2):161-6. PubMed ID: 26961375
    [Abstract] [Full Text] [Related]

  • 2. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
    Olivier CB, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P, Zhou Q, Geisen U, Bode C, Moser M.
    Thromb Res; 2016 Feb; 138():63-68. PubMed ID: 26610745
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.
    Nakazaki M, Oka S, Magota H, Kiyose R, Onodera R, Ukai R, Kataoka-Sasaki Y, Sasaki M, Honmou O.
    J Stroke Cerebrovasc Dis; 2022 Jul; 31(7):106520. PubMed ID: 35523052
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).
    Martischnig AM, Mehilli J, Pollak J, Petzold T, Fiedler AK, Mayer K, Schulz-Schüpke S, Sibbing D, Massberg S, Kastrati A, Sarafoff N.
    Biomed Res Int; 2015 Jul; 2015():798486. PubMed ID: 26229963
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
    Nardin M, Verdoia M, Sartori C, Pergolini P, Rolla R, Barbieri L, Schaffer A, Marino P, Bellomo G, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group.
    J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
    [Abstract] [Full Text] [Related]

  • 8. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
    Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A, Kastrati A, von Beckerath N.
    Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC, Jiang X.
    Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
    [Abstract] [Full Text] [Related]

  • 13. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
    Verdoia M, Pergolini P, Rolla R, Nardin M, Barbieri L, Schaffer A, Bellomo G, Marino P, Suryapranata H, De Luca G.
    Expert Opin Pharmacother; 2015 Aug; 16(12):1739-47. PubMed ID: 26067422
    [Abstract] [Full Text] [Related]

  • 14. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
    Rubboli A, Agewall S, Huber K, Lip GY.
    Int J Cardiol; 2015 Oct 01; 196():133-8. PubMed ID: 26093527
    [Abstract] [Full Text] [Related]

  • 15. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB, Diehl P, Schnabel K, Weik P, Zhou Q, Bode C, Moser M.
    Thromb Haemost; 2014 Feb 01; 111(2):266-72. PubMed ID: 24172891
    [Abstract] [Full Text] [Related]

  • 16. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study.
    Velik-Salchner C, Maier S, Innerhofer P, Streif W, Klingler A, Kolbitsch C, Fries D.
    Anesth Analg; 2008 Dec 01; 107(6):1798-806. PubMed ID: 19020120
    [Abstract] [Full Text] [Related]

  • 17. Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy.
    Gremmel T, Koppensteiner R, Panzer S.
    PLoS One; 2015 Dec 01; 10(6):e0129666. PubMed ID: 26058047
    [Abstract] [Full Text] [Related]

  • 18. Uric acid and high-residual platelet reactivity in patients treated with clopidogrel or ticagrelor.
    Barbieri L, Verdoia M, Pergolini P, Nardin M, Rolla R, Marino P, Bellomo G, Suryapranata H, De Luca G, Novara Atherosclerosis Study Group (NAS).
    Nutr Metab Cardiovasc Dis; 2016 Apr 01; 26(4):352-8. PubMed ID: 26857781
    [Abstract] [Full Text] [Related]

  • 19. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor.
    Hansson EC, Shams Hakimi C, Åström-Olsson K, Hesse C, Wallén H, Dellborg M, Albertsson P, Jeppsson A.
    Br J Anaesth; 2014 Mar 01; 112(3):570-5. PubMed ID: 24148324
    [Abstract] [Full Text] [Related]

  • 20. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
    Stöllberger C, Finsterer J.
    Herz; 2015 Apr 01; 40 Suppl 2():140-5. PubMed ID: 25616425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.